Movement Alert｜BIOCYTOGEN-B Rises 9.45% in Regular Trading, H1 Net Profit Expected to Surge Up to 413%

Market Focus08-07

On August 7, BIOCYTOGEN-B rose 9.45% in regular trading, reaching HKD 60.85 per share, with turnover of HKD 168 million.

On the news front, the company issued a profit forecast indicating that first-half revenue is expected to reach RMB 936-946 million, representing a year-on-year increase of 51%-52%. Net profit attributable to owners is projected at RMB 236-246 million, a surge of 392%-413% compared with approximately RMB 48 million in the prior-year period. Notably, the company had already achieved RMB 104 million in attributable net profit in Q1, marking a turnaround from loss to profit on a year-on-year basis.

The strong performance is driven by dual growth engines in its model animal (BioMice) and antibody development (RenBiologics) business lines. As of end of last year, the company had cumulatively signed over 350 drug co-development, licensing, and transfer agreements, accelerating scalable profitability. Recent strategic collaborations, including a global BsADC partnership with Whitehawk Therapeutics, further reinforce its commercialization momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166941849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 15:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166941849","market":"us","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 9.45% in Regular Trading, H1 Net Profit Expected to Surge Up to 413%","media":"Market Focus","content":"<p><p>On August 7, BIOCYTOGEN-B rose 9.45% in regular trading, reaching HKD 60.85 per share, with turnover of HKD 168 million.</p><p>On the news front, the company issued a profit forecast indicating that first-half revenue is expected to reach RMB 936-946 million, representing a year-on-year increase of 51%-52%. Net profit attributable to owners is projected at RMB 236-246 million, a surge of 392%-413% compared with approximately RMB 48 million in the prior-year period. Notably, the company had already achieved RMB 104 million in attributable net profit in Q1, marking a turnaround from loss to profit on a year-on-year basis.</p><p>The strong performance is driven by dual growth engines in its model animal (BioMice) and antibody development (RenBiologics) business lines. As of end of last year, the company had cumulatively signed over 350 drug co-development, licensing, and transfer agreements, accelerating scalable profitability. Recent strategic collaborations, including a global BsADC partnership with Whitehawk Therapeutics, further reinforce its commercialization momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 9.45% in Regular Trading, H1 Net Profit Expected to Surge Up to 413%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 9.45% in Regular Trading, H1 Net Profit Expected to Surge Up to 413%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 15:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, BIOCYTOGEN-B rose 9.45% in regular trading, reaching HKD 60.85 per share, with turnover of HKD 168 million.</p><p>On the news front, the company issued a profit forecast indicating that first-half revenue is expected to reach RMB 936-946 million, representing a year-on-year increase of 51%-52%. Net profit attributable to owners is projected at RMB 236-246 million, a surge of 392%-413% compared with approximately RMB 48 million in the prior-year period. Notably, the company had already achieved RMB 104 million in attributable net profit in Q1, marking a turnaround from loss to profit on a year-on-year basis.</p><p>The strong performance is driven by dual growth engines in its model animal (BioMice) and antibody development (RenBiologics) business lines. As of end of last year, the company had cumulatively signed over 350 drug co-development, licensing, and transfer agreements, accelerating scalable profitability. Recent strategic collaborations, including a global BsADC partnership with Whitehawk Therapeutics, further reinforce its commercialization momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1166941849","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166941849","pubTimestamp":1786086322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, BIOCYTOGEN-B rose 9.45% in regular trading, reaching HKD 60.85 per share, with turnover of HKD 168 million.On the news front, the company issued a profit forecast indicating that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势预警|BIOCYTOGEN-B 常规交易上涨 9.45%，上半年净利预计飙升至 413%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 7, BIOCYTOGEN-B rose 9.45% in regular trading, reaching HKD 60.85 per share, with turnover of HKD 168 million.On the news front, the company issued a profit forecast indicating that first-half revenue is expected to reach RMB 936-946 million, representing a year-on-year increase of 51%-52%. Net profit attributable to owners is projected at RMB 236-246 million, a surge of 392%-413% compared with approximately RMB 48 million in the prior-year period. Notably, the company had already achieved RMB 104 million in attributable net profit in Q1, marking a turnaround from loss to profit on a year-on-year basis.The strong performance is driven by dual growth engines in its model animal (BioMice) and antibody development (RenBiologics) business lines. As of end of last year, the company had cumulatively signed over 350 drug co-development, licensing, and transfer agreements, accelerating scalable profitability. Recent strategic collaborations, including a global BsADC partnership with Whitehawk Therapeutics, further reinforce its commercialization momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166941849","isCrawlerRequest":true}